What is the evidence base for BPC-157 Capsule (Delayed Release)?

BPC-157 Capsule (Delayed Release)'s evidence base sits at preclinical + limited human. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The longevity / hallmarks of aging interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What is the regulatory status of BPC-157 Capsule (Delayed Release)?

BPC-157 Capsule (Delayed Release) regulatory status: Unapproved (Research Only) in the United States; WADA status banned (2022→); research level preclinical + limited human. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does BPC-157 Capsule (Delayed Release)'s half-life affect dosing?

BPC-157 Capsule (Delayed Release) has a plasma half-life of ~4 hr, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1x daily am, fasted dosing at 500 mcg-1 mg per dose explains the typical onset timeline for healthspan and biological-age endpoints.

What are the safety considerations for BPC-157 Capsule (Delayed Release)?

Same profile as injectable BPC-157. Best taken away from food for absorption. For healthspan and biological-age use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. BPC-157 Capsule (Delayed Release)'s ~4 hr pharmacokinetic profile and oral administration route influence the side-effect profile in predictable ways.

How should BPC-157 Capsule (Delayed Release) be stored and reconstituted?

Lyophilised BPC-157 Capsule (Delayed Release) stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Home/ Compounds/ BPC-157 Capsule (Delayed Release)

BPC-157 Capsule (Delayed Release)

Longevity

For users tracking biological age and healthspan-relevant biomarkers, BPC-157 Capsule (Delayed Release) sits within a multi-component longevity framework spanning hallmarks-of-aging from cellular (telomere, senescence, mitochondrial) through integrative (inflammaging, nutrient sensing). An oral delayed-release format of BPC-157 optimized for gut-targeted action and gut-brain axis effects. Cycle-based dosing over 8-12 weeks with pre-post biomarker tracking is the longevity-research convention.

Longevity / Hallmarks of Aging Applications

ProteostasismTOR ModulationEpigenetic AgingStem Cell FunctionAutophagy Induction

Key Takeaways

Longevity lens: BPC-157 Capsule (Delayed Release) maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Same pentadecapeptide as injectable BPC-157, formulated for delayed release in the small intestine.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 500 mcg-1 mg 1x daily am, fasted dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

Same pentadecapeptide as injectable BPC-157, formulated for delayed release in the small intestine. Engages enteric receptors directly, supporting gut barrier integrity and signalling along the vagal gut-brain axis. Hallmarks-of-aging mapping for BPC-157 Capsule (Delayed Release): which of the nine hallmarks does this mechanism engage? The subsections below address BPC-157 Capsule (Delayed Release)'s mapping to the hallmark framework, its effects on cellular reprogramming and gene expression, healthspan biomarker movement, and the cycle-based versus continuous dosing question that frames longevity-research protocol design.

Cycle-based versus continuous dosing

BPC-157 Capsule (Delayed Release)'s longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Mapping to the hallmarks of aging

BPC-157 Capsule (Delayed Release)'s longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Same pentadecapeptide as injectable BPC-157, formulated for delayed release in the small intestine. Engages enteric receptors directly, supporting gut barrier integrity and signalling along the vagal gut-brain axis. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Cellular reprogramming and gene expression

Where BPC-157 Capsule (Delayed Release) has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Longevity / Hallmarks of Aging Applications

Nutrient Sensing

Nutrient Sensing maps to one of the hallmarks of aging and is one of the dimensions on which BPC-157 Capsule (Delayed Release) is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

mTOR Modulation

For mtor modulation as a longevity-relevant endpoint, BPC-157 Capsule (Delayed Release) is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Autophagy Induction

BPC-157 Capsule (Delayed Release)'s contribution to autophagy induction as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Stem Cell Function

Stem Cell Function maps to one of the hallmarks of aging and is one of the dimensions on which BPC-157 Capsule (Delayed Release) is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Oral	500 mcg-1 mg	8–12 weeks on / 4 weeks off
Conservative starter	Oral	300 mcg-1 mg	4–6 weeks initial cycle
Longevity focus	Oral	500 mcg-1 mg	1x daily AM, fasted
Maintenance phase	Oral	350 mcg-1 mg	Ongoing with periodic pauses

Dose timing for BPC-157 Capsule (Delayed Release) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

BPC-157 Capsule (Delayed Release) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

BPC-157 Capsule (Delayed Release) + Epithalon: Identified by Khavinson in St. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in longevity / hallmarks of aging protocols.
BPC-157 Capsule (Delayed Release) + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in longevity / hallmarks of aging protocols.
BPC-157 Capsule (Delayed Release) + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in longevity / hallmarks of aging protocols.
BPC-157 Capsule (Delayed Release) + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Banned (2022→) FDA: Unapproved (Research Only) Research: Preclinical + Limited Human

Same profile as injectable BPC-157. Best taken away from food for absorption.

Lens-specific safety considerations for longevity / hallmarks of aging use of BPC-157 Capsule (Delayed Release): Same profile as injectable BPC-157. Best taken away from food for absorption. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Sikirić et al. — BPC 157 cytoprotection and tissue repair

PMID 10404425

Supporting

BPC 157: clinical applications and mechanism

PMID 34209680

BPC-157 Capsule (Delayed Release) vs Related Peptides

Compound	Profile	Onset	Best For
BPC-157 Capsule (Delayed Release)	Stable gastric pentadecapeptide (oral)	~4 hr	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Does BPC-157 Capsule (Delayed Release) actually extend lifespan?

Direct lifespan extension in humans cannot be inferred from current data for any peptide compound. The relevant question is whether BPC-157 Capsule (Delayed Release) measurably moves healthspan-relevant biomarkers — epigenetic age, telomere length, inflammatory panels, metabolic flexibility — in the direction of younger phenotypes. Some compounds in this class have measurable effects on these markers; the lifespan extrapolation remains inferential.

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). BPC-157 Capsule (Delayed Release) contributes to its specific hallmark layer in this multi-component framework.

When in life should I start BPC-157 Capsule (Delayed Release)?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

What are the long-term safety considerations?

Long-term safety data for most peptide compounds is limited to a small number of well-studied molecules with multi-decade clinical observation. For most others, the long-term framework relies on mechanism-based risk assessment plus accumulating clinical experience. Cycle-based dosing and periodic re-evaluation are appropriate for compounds without 10+ year human safety data.

What does BPC-157 Capsule (Delayed Release) stack well with?

For longevity / hallmarks of aging protocols, BPC-157 Capsule (Delayed Release) pairs with compounds on complementary pathways: Epithalon, Thymalin, NAD+. These pairings are selected because they engage independent receptor systems from BPC-157 Capsule (Delayed Release)'s primary mechanism (Same pentadecapeptide as injectable BPC-157, formulated for delayed release in the small intestine), producing additive or synergistic effects rather than receptor competition.

Is BPC-157 Capsule (Delayed Release) safe during pregnancy or breastfeeding?

BPC-157 Capsule (Delayed Release), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Clinical Protocol

Start a BPC-157 Capsule (Delayed Release) Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified BPC-157 Capsule (Delayed Release) and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 1419.5 Da
Sequence length: 15 aa
Half-life: ~4 hr
WADA: Banned (2022→)
FDA: Unapproved (Research Only)
Research: Preclinical + Limited Human

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for BPC-157 Capsule (Delayed Release) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for BPC-157 Capsule (Delayed Release)

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised